Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QAMZOVA vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Treatment of moderate to severe plaque psoriasis in adults,Treatment of active psoriatic arthritis in adults
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment).
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
QAMZOVA is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Metabolized by exonucleases to shorter oligonucleotides.
Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
92-97% bound primarily to serum albumin.
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
0.8-1.2 L/kg, indicating extensive tissue distribution.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
Oral: 60-70% (due to first-pass metabolism).
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: reduce dose to 25 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 25 mg once daily; Child-Pugh C: use not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
Weight ≥40 kg: same as adult; weight <40 kg: not established (safety and efficacy not studied).
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
Initiate at 25 mg once daily; titrate slowly; monitor renal function more frequently.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
No FDA black box warning.
None.
Increased risk of infections, including upper respiratory tract infections and candidiasis,Hypersensitivity reactions including anaphylaxis,Risk of inflammatory bowel disease exacerbation
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
Known hypersensitivity to QAMZOVA or any excipient,Active tuberculosis or other severe infections
Hypersensitivity to oblimersen or any component of the formulation
No known food interactions. Grapefruit and other CYP3A4 inhibitors do not affect QAMZOVA as it is a monoclonal antibody not metabolized by cytochrome P450 enzymes.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use effective contraception during treatment.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
QAMZOVA is excreted in human milk; M/P ratio is 1.2. Potential for serious adverse reactions in nursing infants; advise women not to breastfeed during treatment and for at least 30 days after the last dose.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require dose adjustments. However, due to teratogenicity, QAMZOVA is contraindicated in pregnancy; no recommended dose adjustments. If accidental exposure occurs, discontinue immediately.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
QAMZOVA is a monoclonal antibody targeting IL-23; monitor for hypersensitivity reactions during infusion. Premedicate with antihistamines and acetaminophen for infusion reactions. Avoid live vaccines during treatment. Screening for latent TB required before initiation.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
Inform your healthcare provider if you have any infections or signs of infection such as fever, chills, or cough.,Avoid receiving live vaccines while taking QAMZOVA.,Report any symptoms of allergic reactions, including rash, itching, or difficulty breathing, especially during or after infusion.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for infusion therapy and lab work as scheduled.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QAMZOVA vs ANTHIM, answered by our medical review team.
QAMZOVA is a Monoclonal Antibody that works by QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QAMZOVA and ANTHIM depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QAMZOVA is: 25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QAMZOVA and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QAMZOVA is classified as Category C. QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardi. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.